Arianna Cafarotti1, Alessandro Fiocchi, Stefania Arasi. 1. Translational Research in Pediatric Specialities Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio, Rome, Italy.
Abstract
PURPOSE OF REVIEW: To provide the most recent insights in the use of biologicals in the treatment of patients with anaphylaxis. RECENT FINDINGS: There is evidence that biologics such as omalizumab may be safe and effective in preventing anaphylactic reactions in patients at high risk mainly because of severe food allergy or desensitization procedures to food, airborne allergen, drugs, or hymenoptera venom. SUMMARY: Further knowledge will guide the adoption and implementation of any new therapy including biologics for anaphylaxis according to the stratification of risk/benefits.
PURPOSE OF REVIEW: To provide the most recent insights in the use of biologicals in the treatment of patients with anaphylaxis. RECENT FINDINGS: There is evidence that biologics such as omalizumab may be safe and effective in preventing anaphylactic reactions in patients at high risk mainly because of severe food allergy or desensitization procedures to food, airborne allergen, drugs, or hymenoptera venom. SUMMARY: Further knowledge will guide the adoption and implementation of any new therapy including biologics for anaphylaxis according to the stratification of risk/benefits.